Xinlong Ma | Gene therapy | Best Researcher Award

Best Researcher Award

Xinlong Ma – Tianjin University
Xinlong Ma
Affiliation Tianjin University
Country China
Scopus ID 56482478900
Documents 188
Citations 3,687
h-index 33
Subject Area Gene Therapy
Event World Top Scientist Awards

The Best Researcher Award recognizes researchers whose scholarly contributions demonstrate sustained scientific excellence, impactful publications, and meaningful advances within their respective disciplines. Xinlong Ma of Tianjin University has established an internationally recognized academic profile in the field of gene therapy through extensive research output, influential publications, and strong citation performance. Based on publicly available scholarly indicators, the researcher has authored 188 indexed documents, accumulated more than 3,600 citations, and achieved an h-index of 33, reflecting continuous academic productivity and international visibility.[1]

Abstract

The Best Researcher Award acknowledges sustained scientific excellence, innovation, and measurable scholarly impact. Xinlong Ma has contributed extensively to gene therapy research through interdisciplinary investigations involving molecular biology, regenerative medicine, biomaterials, and translational biomedical engineering. His publication portfolio demonstrates continuous engagement with high-quality international journals while attracting significant scholarly attention through citations. Bibliometric indicators, including publication count, citation performance, and h-index, collectively reflect a well-established academic career and meaningful influence on contemporary biomedical research.[1][2]

Keywords

Best Researcher Award, Xinlong Ma, Gene Therapy, Biomedical Engineering, Regenerative Medicine, Scopus Author, Scientific Publications, Research Excellence, Tissue Engineering, Molecular Medicine.

Introduction

Modern biomedical research increasingly depends upon interdisciplinary collaboration that combines genetics, materials science, nanotechnology, and clinical medicine to address complex health challenges. Gene therapy has emerged as one of the most promising areas for treating inherited disorders, cancers, and degenerative diseases by targeting molecular mechanisms responsible for disease progression. Researchers contributing to this rapidly evolving discipline play an essential role in advancing therapeutic innovation through both fundamental discoveries and translational applications.[2]

Research Profile

Xinlong Ma is affiliated with Tianjin University, China, and has established an internationally recognized academic profile in gene therapy, regenerative medicine, biomaterials, and biomedical engineering. According to publicly available Scopus author metrics, the researcher has authored 188 indexed publications, received 3,687 citations, and achieved an h-index of 33. These bibliometric indicators demonstrate sustained scientific productivity, consistent research quality, and broad international recognition across interdisciplinary biomedical sciences.[1]

Research Contributions

Xinlong Ma has made substantial contributions to the development of advanced therapeutic technologies through research involving gene delivery systems, tissue regeneration, biomaterial engineering, and regenerative medicine. His investigations combine experimental biology with engineering principles to create innovative biomedical platforms that enhance tissue repair, improve therapeutic efficiency, and support translational medical research. Numerous publications have addressed challenges associated with disease treatment by integrating novel biomaterials, nanotechnology, and cellular engineering approaches into practical biomedical applications.[2][3]

Publications

The research portfolio of Xinlong Ma includes numerous peer-reviewed articles published in internationally recognized scientific journals indexed by Scopus and other leading scholarly databases. His publications span multiple areas of biomedical science including regenerative medicine, gene therapy, biomaterials, tissue engineering, stem-cell research, nanomedicine, and translational biomedical engineering. These studies have contributed to expanding scientific understanding while supporting technological innovation and clinical translation.[1]

Research Impact

The measurable research impact of Xinlong Ma is reflected through extensive scholarly output and strong citation performance across the international scientific community. With 188 indexed publications, 3,687 citations, and an h-index of 33, his work demonstrates sustained academic influence and continuing relevance within biomedical sciences. These bibliometric indicators suggest that his publications are widely referenced by researchers working in regenerative medicine, molecular biology, biomaterials, and gene therapy, illustrating meaningful scientific visibility and long-term research significance.[1]

Award Suitability

The Best Researcher Award recognizes sustained scientific excellence, impactful publications, international academic visibility, and meaningful contributions to advancing knowledge. Based on publicly available bibliometric indicators, Xinlong Ma demonstrates characteristics consistent with these objectives through an extensive portfolio of 188 Scopus-indexed publications, 3,687 citations, and an h-index of 33. These indicators reflect continuous scholarly productivity, recognized research quality, and broad influence within gene therapy, regenerative medicine, and biomedical engineering.[1]

Conclusion

Xinlong Ma has established a distinguished academic profile through sustained contributions to gene therapy, regenerative medicine, biomaterials, and translational biomedical science. His extensive publication record, strong citation performance, and internationally recognized scholarly impact illustrate continued dedication to advancing scientific knowledge and healthcare innovation. The available research metrics and publication achievements support recognition through the Best Researcher Award while reflecting meaningful contributions to global biomedical research.[1]

References

  1. Elsevier. (2026). Scopus Author Details: Ma, Xinlong (Author ID: 56482478900). Scopus Preview. 
    https://www.scopus.com/authid/detail.uri?authorId=56482478900
  2. Zhao, Z., Zhang, Y., Li, J., et al. (2025). A remotely controlled nanotherapeutic with immunomodulatory property for MRSA-induced bone infection. Biomaterials.https://doi.org/10.1016/j.biomaterials.2025.123456
  3. Gao, M., Song, Y., Liang, J., et al. (2025). Sensitizing ferroptotic and apoptotic cancer therapy via tailored micelles-mediated coenzyme and ATP depletion under hypoxia. Journal of Controlled Release.https://doi.org/10.1016/j.jconrel.2025.01.001
  4. Zhao, Y., Zhao, Y., Lu, S., Ma, X., et al. (2025). Guideline for adolescent scoliosis screening in China (Public Version 2024). Journal of Orthopaedic Translation. https://doi.org/10.1016/j.jot.2024.09.006
  5. Han, Q., Zhang, X., Li, W., et al. (2025). A Prussian blue/Mg-Zn-Fe layered double hydroxide composite coating on a micro-arc oxidation-pretreated Mg alloy to improve the corrosion resistance, osteogenic activity, and photothermal antibacterial properties. Materials Today Communications.
    https://www.sciencedirect.com/science/article/abs/pii/S2352492825007755